Many patients find Semaglutide more convenient, but our team can help you evaluate both if not all options
And they can adjust that schedule over time if need be
After starting Semaglutide GLP-1 , many patients begin to notice a decrease in appetite within the first week of treatment
Beyond thyroidal hyperfunction, Graves disease may manifest with extra-thyroidal complications, most notably thyroid-associated orbitopathy, in which fibroblasts and preadipocytes in the orbit express the TSHR and insulin-like growth factor 1 receptor (IGF-1R), leading to tissue expansion, edema, and fibrosis under autoantibody stimulation [19,20]
Patients with Graves disease should have stable, controlled thyroid function before undergoing elective bariatric surgery, and endocrinology consultation is recommended for perioperative management